ADARx Pharmaceuticals (NASDAQ:ADRX) Stock: Insider Orbimed Advisors Llc Buys 950,000 Shares

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Orbimed Advisors Llc acquired 950,000 shares of the stock in a transaction on Monday, September 28th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $16,150,000.00. Following the completion of the transaction, the director directly owned 14,325,529 shares in the company, valued at $243,533,993. The trade was a 7.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

ADARx Pharmaceuticals Stock Down 3.4%

Shares of NASDAQ:ADRX traded down $0.70 on Wednesday, reaching $19.94. The company’s stock had a trading volume of 788,778 shares, compared to its average volume of 1,097,539. ADARx Pharmaceuticals, Inc. has a 52-week low of $18.50 and a 52-week high of $23.21.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.